The total number of records retrieved from this search are 15. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_669	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 3 Gy (synergism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman cutaneous melanoma cell line	Cell linePMWK	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.001 MOI	In-vitro result98% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_670	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 3 Gy (synergism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman cutaneous melanoma cell line	Cell linePMWK	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result78% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_671	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 3 Gy (synergism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman cutaneous melanoma cell line	Cell linePMWK	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result60% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_672	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 3 Gy (synergism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman cutaneous melanoma cell line	Cell linePMWK	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.5 MOI	In-vitro result20% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_673	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 3 Gy (synergism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman cutaneous melanoma cell line	Cell linePMWK	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result12% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_674	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 5 Gy (synergism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman cutaneous melanoma cell line	Cell linePMWK	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.001 MOI	In-vitro result70% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_675	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 5 Gy (synergism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman cutaneous melanoma cell line	Cell linePMWK	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result60% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_676	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 5 Gy (synergism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman cutaneous melanoma cell line	Cell linePMWK	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result17% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_677	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 5 Gy (synergism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman cutaneous melanoma cell line	Cell linePMWK	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.5 MOI	In-vitro result8% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_678	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with radiation, 5 Gy (synergism)	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman cutaneous melanoma cell line	Cell linePMWK	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result8% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_704	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman cutaneous melanoma cell line	Cell linePMWK	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.001 MOI	In-vitro result110% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_705	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman cutaneous melanoma cell line	Cell linePMWK	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result92% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_706	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman cutaneous melanoma cell line	Cell linePMWK	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result70% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_707	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman cutaneous melanoma cell line	Cell linePMWK	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.5 MOI	In-vitro result25% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486
IDOV_708	Virus nameReovirus	Virus strainRT3D (Reolysin)	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineProf. Richard Marais lab	Origin of cell lineHuman cutaneous melanoma cell line	Cell linePMWK	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result19% cancer cell viability (calculated as relative to non-infected group)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedDown-regulation of the inhibitor of apoptosis (IAP) family of proteins with a corresponding increase in cleaved caspase 9/3	Immunogenic effectNA	Clinical trialNA	PMID27384486